Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on safety, pharmacokinetics, and pharmacodynamics of ruzasvir (MK-8408) in participants with hepatitis C infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ruzasvir (ruzasvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C Infection | Phase 1 | Status: COMPLETED | Results posted: 2018-11-28